da Calogero Calcullo | Apr 10, 2016 | Novità dalla letteratura, Rubriche
Most physician readers of Aro’s and Chugh’s elegant review of electrical and anatomic types of LVH and the implications will be puzzled by the concepts that electrical LVH (ECG/LVH) and anatomic LVH (echo/LVH and MRI/LVH) might be different entities, and that patients...
da Calogero Calcullo | Apr 1, 2016 | Cardiologia: presente e futuro... Discutiamone, Novità dalla letteratura, Rubriche
Patients with heart failure have a poor prognosis, yet outcomes might be improved by early identification of risk. Proenkephalin (proENK), a novel biomarker, is a stable surrogate marker for endogenous enkephalins and is an independent predictor of heart failure and...
da Calogero Calcullo | Mar 16, 2016 | Archivio Eventi patrocinati da ANCE
23 – 25 Marzo 2016 Villa Barile Caltanissetta vedi dettagli
da Calogero Calcullo | Mar 16, 2016 | Rubriche
We aim to evaluate the potential benefit and risk of addition of vorapaxar to standard medical therapy in patients who underwent coronary revascularization with either percutaneous coronary revascularization or coronary artery bypass graft surgery. We searched PubMed,...
da Calogero Calcullo | Mar 16, 2016 | Novità dalla letteratura, Rubriche
Dopo l’endorsement dei giorni scorsi ricevuto dello staff interno dell’Fda, lo scorso 15 gennaio il nuovo antiaggregante orale vorapaxar ha ricevuto il parere positivo degli esperti del Cardiovascular and Renal Drugs Advisory Committee dell’Fda. Con 10 voti a 1, gli...
